Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KALA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$6.40-2.6%$7.41$5.10▼$19.35$18.05M-1.8525,714 shs1,078 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO+2.69%-5.66%-18.65%-9.34%-58.73%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALAKALA BIO3.6179 of 5 stars3.55.00.04.40.00.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO3.00Buy$18.00181.25% UpsideCurrent Analyst RatingsLatest KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BIO$3.89M4.64N/AN/A$2.79 per share2.29Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)Latest KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BIO5.106.336.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO13.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO432.82 million2.44 millionNot OptionableKALA HeadlinesSourceHeadlineReba McEntire Uses This Wrinkle-Targeting Moisturizer for Smooth, Glowing Skin at 69msn.com - April 22 at 5:16 PMTravis Kelce’s ex Kayla Nicole blasts Taylor Swift’s fans ahead of ‘TTPD’ album release: ‘Everyone has a breaking point’msn.com - April 18 at 6:20 PMNicki Minaj Just Dropped a Sneaker Collection with This Low-Key Brand That Celebs Have Been Wearing for Yearsmsn.com - April 16 at 12:40 AMBlind amputee pushes his limitsscottsdale.org - April 14 at 7:32 AMWhat can you do with unwanted holy cards and Grandma’s religious statues?msn.com - April 13 at 3:58 PMGrace Charis' net worth and biography: Meet the TikTok golf starmsn.com - April 12 at 7:23 AMIMPACT Tallahassee is raising money for renovation and expansionnews.wfsu.org - April 11 at 10:09 AMWant to spend Poila Baisakh outdoors? Start the Bengali New Year with these events in Kolkatatelegraphindia.com - April 11 at 10:09 AMNYC extends DocGo's $432M migrant contract another seven monthstimesunion.com - April 11 at 10:09 AMValerie Bertinelli, 63, Shares Stance on Ozempic and Trying to Lose ‘10 Pounds in a Week’msn.com - April 11 at 10:09 AM‘Shark Tank’ Star Barbara Corcoran Opens Up About Facelifts and Cosmetic Surgerymsn.com - April 11 at 10:09 AMKala Pharmaceuticals gets grant for ocular treatment method using msc-derived fibronectin compositionpharmaceutical-technology.com - April 10 at 1:14 PMI tried $1,441 worth of products from Sephora — here's what I'm re-buying (and skipping) from the spring saleca.style.yahoo.com - April 6 at 5:27 PMDoes KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?zacks.com - April 4 at 10:56 AMHomegrown hit: Mercury Theater Chicago’s ‘Jersey Boys’ is a must-seedailyherald.com - April 4 at 7:24 AM20 famous female celebrities struggling with hair lossmsn.com - April 3 at 9:44 AMShehnaaz Gill, Now A Playback Singer, Celebrated Her First Song's Release Like Thisndtv.com - April 3 at 9:44 AM8 Former Child Stars Who've Moved On to 'Typical' (and Impressive!) Day Jobsca.finance.yahoo.com - April 2 at 8:04 PMMakeup Artist Trinny Woodall, 60, Shares ‘Foolproof’ Spring Beauty Tips for All Agesmsn.com - March 30 at 1:45 PMKALA BIO, Inc.: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 29 at 10:31 AMKALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 29 at 8:00 AM13 Best Brasil OnlyFans Featuring/With Brasil OnlyFans in 2024riverfronttimes.com - March 29 at 12:30 AMAmazon's Big Spring Sale is over, but these 40 extended deals are just as good — up to 73% off tech, home & moreca.style.yahoo.com - March 28 at 7:30 PMRemembering the luminary: Here's how KPAC Sulochana and the golden years of theatre influenced Keralamsn.com - March 28 at 7:30 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsKALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
